Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial

British Journal of Cancer

Volumn 103, Issue 10, 2010, Pages 1542-1547

  Garufi, C ^a   Torsello, A ^a   Tumolo, S ^b   Ettorre, G M ^c   Zeuli, M ^a   Campanella, C ^a   Vennarecci, G ^c   Mottolese, M ^a   Sperduti, I ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

cetuximab; chronotherapy; colorectal liver metastases; liver resectability; neoadjuvant chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AFEBRILE NEUTROPENIA; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGANOPLATINUM COMPOUNDS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESEARCH DESIGN; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78149469673     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605940     Document Type: Article

References (23)

1. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4): 644-657, (discussion 657-648)
2. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH (2005) Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 23(36): 9243-9249
3. Bismuth H, Adam R, Lévi F, Farabos C, Waechter F, Castaing D, Majno P, Engerran L (1996) Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224(4): 509-520, (discussion 520-502)
4. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5): 663-671
5. Bouchahda M, Adam R, Giacchetti S, Castaing D, Brezault-Bonnet C, Hauteville D, Innominato PF, Focan C, Machover D, Lévi F (2009) Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer 115(21): 4990-4999
6. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11): 1160-1174
7. De la Cámara J, Rodriguez J, Rotellar F, Viudez A, García-Foncillas J, Pardo F, Gíl-Bazo I, Chopitea A, Martín-Algara S (2004) triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 22(14S): abstract 3593
8. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G (2007) Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 25(13): 1670-1676
9. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. (2005) Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 16(8): 1311-1319
10. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH (2010) Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 11(1): 38-47
11. Garufi C, Bria E, Vanni B, Zappala AM, Sperduti I, Terzoli E (2003) A phase II study of irinotecan plus chronomodulated oxaliplatin. Br J Cancer 89(10): 1870-1875
12. Garufi C, Focan C, Tumolo S, Coudert B, Iacobelli S, Tubiana N, Merreaud S, Lentz M, Gorlia T, Levi F (2007) Time finding study of chronomodulated irinotecan (I), fluorouracil, (F), leucovorin (L) and oxaliplatin (O) (chrono-IFLO) against metastatic colorectal cancer: results from randomized EORTC 05011 trial. J Clin Oncol 25(18S): abstract 2566
13. Garufi C, Torsello A, Campanella C, Ettorre GM, Vennarecci G, Melucci, Zeuli M, Sperduti I, Gelibter A, Cognetti F (2010) CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) plus cetux-imab (Cmab) in unselected advanced colorectal cancer (ACC) patients. J Clin Oncol 28(15S): abstract 3551
14. Gholam D, Giacchetti S, Brézault-Bonnet C, Bouchahda M, Hauteville D, Adam R, Ducot B, Ghémard O, Kustlinger F, Jasmin C, Lévi F (2006) Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irino-tecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 11(10): 1072-1080
15. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, Smaaland R, Focan C, Coudert B, Humblet Y, Canon JL, Adenis A, Lo Re G, Carvalho C, Schueller J, Anciaux N, Lentz MA, Baron B, Gorlia T, Lévi F (2006) Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. J Clin Oncol 24(22): 3562-3569
16. 0Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F (2002) Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 86(6): 999-1005
17. Lévi F (2001) Circadian chronotherapy for human cancers. Lancet Oncol 2: 307-315
18. Levi F, Innominato P, Poncet A, Moreau T, Iacobelli S, Focan C, Garufi C, Bjarnason G, Adam R, Giacchetti S. (2009) Meta-analysis of gender effect for first-line chronomodulated 5-fluorouracil-leucovorin-oxaliplatin (ChronoFLO) compared with FOLFOX or constant infusion (conventional delivery, CONV) against metastatic colorectal cancer (MCC) in three international controlled phase III randomized trials (RT). J Clin Oncol 27(15S): abstract 4112
19. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A (2010) Bevacizmab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 9 [E-pub ahead of print]
20. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19): 1308-1324
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216
22. 0Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14): 1408-1417
23. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quenet F, Portier G (2008) Tritherapy with fluorouracil/ laucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 62(2): 195-201